Codexis (CDXS) Competitors $5.28 +0.16 (+3.13%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CDXS vs. CLDX, MNKD, DVAX, BCRX, NVAX, MYGN, INVA, OPK, IRWD, and SGMOShould you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Celldex Therapeutics (CLDX), MannKind (MNKD), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Myriad Genetics (MYGN), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), and Sangamo Therapeutics (SGMO). These companies are all part of the "biotechnology" industry. Codexis vs. Celldex Therapeutics MannKind Dynavax Technologies BioCryst Pharmaceuticals Novavax Myriad Genetics Innoviva OPKO Health Ironwood Pharmaceuticals Sangamo Therapeutics Celldex Therapeutics (NASDAQ:CLDX) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk. Do institutionals & insiders believe in CLDX or CDXS? 78.5% of Codexis shares are held by institutional investors. 3.8% of Celldex Therapeutics shares are held by company insiders. Comparatively, 2.1% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is CLDX or CDXS more profitable? Codexis has a net margin of -96.35% compared to Celldex Therapeutics' net margin of -1,544.32%. Celldex Therapeutics' return on equity of -19.75% beat Codexis' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-1,544.32% -19.75% -18.86% Codexis -96.35%-71.56%-38.00% Does the media prefer CLDX or CDXS? In the previous week, Celldex Therapeutics had 7 more articles in the media than Codexis. MarketBeat recorded 8 mentions for Celldex Therapeutics and 1 mentions for Codexis. Codexis' average media sentiment score of 0.78 beat Celldex Therapeutics' score of 0.61 indicating that Codexis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Codexis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer CLDX or CDXS? Celldex Therapeutics received 267 more outperform votes than Codexis when rated by MarketBeat users. Likewise, 75.18% of users gave Celldex Therapeutics an outperform vote while only 61.47% of users gave Codexis an outperform vote. CompanyUnderperformOutperformCelldex TherapeuticsOutperform Votes61875.18% Underperform Votes20424.82% CodexisOutperform Votes35161.47% Underperform Votes22038.53% Which has more risk and volatility, CLDX or CDXS? Celldex Therapeutics has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Codexis has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500. Do analysts prefer CLDX or CDXS? Celldex Therapeutics currently has a consensus target price of $62.25, suggesting a potential upside of 147.61%. Codexis has a consensus target price of $8.33, suggesting a potential upside of 57.83%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Celldex Therapeutics is more favorable than Codexis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Codexis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has stronger valuation & earnings, CLDX or CDXS? Codexis has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$9.98M167.19-$141.43M-$2.57-9.78Codexis$64.45M6.67-$76.24M-$0.87-6.07 SummaryCelldex Therapeutics beats Codexis on 11 of the 19 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDXS vs. The Competition Export to ExcelMetricCodexisIndustrial organic chemicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$429.68M$2.49B$5.12B$9.07BDividend YieldN/A3.50%4.91%4.22%P/E Ratio-6.0714.3291.3417.19Price / Sales6.67993.881,116.59116.80Price / CashN/A29.9142.6437.86Price / Book4.261.534.794.78Net Income-$76.24M$8.51M$120.07M$225.60M7 Day Performance-4.52%-3.22%-1.89%-1.24%1 Month Performance21.94%-8.74%11.45%3.36%1 Year Performance71.99%-24.21%30.61%16.58% Codexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDXSCodexis4.1394 of 5 stars$5.28+3.1%$8.33+57.8%+80.2%$429.68M$64.45M-6.07250High Trading VolumeCLDXCelldex Therapeutics2.6659 of 5 stars$26.26+3.3%$62.25+137.1%-33.5%$1.74B$6.88M-9.89160Analyst ForecastNews CoveragePositive NewsMNKDMannKind3.195 of 5 stars$6.26-4.3%$8.67+38.4%+105.4%$1.73B$267.20M89.29400Analyst UpgradeAnalyst RevisionNews CoverageDVAXDynavax Technologies4.6668 of 5 stars$12.99+0.2%$22.00+69.4%-4.1%$1.71B$260.81M100.00408News CoveragePositive NewsBCRXBioCryst Pharmaceuticals3.7384 of 5 stars$7.36-2.3%$15.60+112.0%+34.2%$1.52B$412.58M-12.34530News CoveragePositive NewsNVAXNovavax3.8239 of 5 stars$9.21+1.1%$17.83+93.6%+77.2%$1.48B$847.25M-4.031,543MYGNMyriad Genetics4.4478 of 5 stars$14.20-1.6%$24.27+70.9%-34.3%$1.29B$823.60M-11.102,700INVAInnoviva1.9799 of 5 stars$18.45-0.7%N/A+11.7%$1.15B$310.46M26.93112OPKOPKO Health4.1754 of 5 stars$1.55-2.8%$2.75+78.0%-1.3%$1.05B$711.41M-8.343,930Analyst UpgradePositive NewsIRWDIronwood Pharmaceuticals4.0588 of 5 stars$3.56+0.8%$10.40+192.1%-59.5%$569.71M$442.73M-117.67220News CoverageSGMOSangamo Therapeutics1.7575 of 5 stars$2.53+23.2%$7.00+177.2%+581.6%$526.84M$176.23M-3.11480Analyst ForecastNews CoverageHigh Trading Volume Related Companies and Tools Related Companies CLDX Alternatives MNKD Alternatives DVAX Alternatives BCRX Alternatives NVAX Alternatives MYGN Alternatives INVA Alternatives OPK Alternatives IRWD Alternatives SGMO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDXS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDXS Stock Alerts